Business Segments · Restructuring
Orthopaedics Restructuring Plan — Restructuring
Johnson & Johnson Orthopaedics Restructuring Plan — Restructuring remained flat by 0.0% to $76.75M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ1 2025
Last reportedQ4 2025
Rolls up toRestructuring Charges
How to read this metric
An increase in restructuring costs typically signals a major strategic pivot or effort to reduce long-term overhead, while a decrease suggests the completion of the transformation phase.
Detailed definition
This metric represents the specific costs and financial impacts associated with the strategic reorganization and operati...
Peer comparison
Similar to 'Restructuring Charges' or 'Transformation Costs' reported by medical device peers like Stryker or Zimmer Biomet when they undergo significant operational realignments.
Metric ID:
jnj_segment_orthopaedics_restructuring_plan_restructuringHistorical Data
1 years
| FY'25 | |
|---|---|
| Value | $307.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's orthopaedics restructuring plan — restructuring?
- Johnson & Johnson (JNJ) reported orthopaedics restructuring plan — restructuring of $76.75M in Q4 2025.
- What does orthopaedics restructuring plan — restructuring mean?
- The total financial costs incurred to reorganize and improve the operational efficiency of the orthopaedics business segment.